Figure 5. Anti‐VEGF therapy led to decreased infiltration of CD68⁺ macrophages in human GBM .

• A–G
  Anti‐CD68 (A), anti‐CSFR1 (B), and anti‐CD206 (C) immunohistochemistry of patient samples derived from treatment‐naive GBM (n = 24), post‐radiochemotherapy (S/RTx/CTx) (n = 7), and post‐radiochemotherapy + bevacizumab (S/RTx/CTx/Bev) (n = 29) therapy are shown. Corresponding quantification of tumor‐infiltrating cells is displayed (anti‐CD68, D), (anti‐CSF1R, E), and (anti‐CD206, F). Ratio of CD206⁺ versus CD68⁺ cells (G).
• H
  Amount of CD206⁺ perivascular cells per blood vessel.
• I
  Double staining of Ang‐2 (brown) and CD206 (red) of a S/RTx/CTx/Bev patient, arrowheads indicating perivascular CD206⁺ cells around Ang‐2⁺ vessels. Arrows pointing on parenchymal CD206⁺ cells.
• J
  CD206⁺ cells in relation to the percentage of hypoxic (CAIX positive) tumor area.

Data information: Statistical analysis: Kruskal–Wallis (Dunn's post‐test). *P < 0.05, ***P < 0.005; data are mean ± SEM. Scale bars (A–C, I): 100 μm.